Bluebird Casts Wide Partnering Net To Keep Advancing Cell Therapy

Cardiologists know PCSK9 inhibition is a powerful LDL-lowering tool and now Amgen’s VESALIUS data show it may be worth adding to the primary care physician’s toolbox for prevention of high-risk patients’ first major cardiovascular events.

The FDA approved the anti-CD38 monoclonal antibody, a mainstay of multiple myeloma for a decade, for high-risk smoldering disease.

Even with Innosera's sweetened offers and a boardroom recommendation, the proposed acquisition could not clear the minimum 66.67% shareholder approval level.

Do US FDA’s efforts at simplifying the biosimilar pathway create more competition and threaten Aurobindo Pharma's return on investments? Management speaks on this, biosimilar filing plans and deal strategy at the Q2 FY26 earnings call